Miromatrix Medical Inc.

Miromatrix Medical Inc. (MIRO) priced its initial public offering on Jun 24, 2021 at $9.00 per share, within its $7.00–$9.00 range, raising $43.2M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $164M. Craig-Hallum was lead-left underwriter. Faegre Drinker advised the company and Fredrikson & Byron advised the underwriters.

Miromatrix Medical Inc. is a life sciences company developing technology to bioengineer fully transplantable human organs. Its perfusion technology platform is aimed at easing the organ shortage, with initial development focused on human livers and kidneys.

Status

IPO

Ticker

MIRO

Exchange

Nasdaq Capital Market

Priced

Jun 24, 2021

IPO price

$9.00

Price range

$7.00–$9.00

Raised

$43.2M

Market cap at IPO price

$164M

First filed

May 28, 2021

Underwriters

Craig-Hallum

Company counsel

Faegre Drinker

Underwriters' counsel

Fredrikson & Byron

Sector

Biotech & pharma

Country / state

MN

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.